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ABSTRACT

The synthesis of bile acids is the major biological mechanism for cholesterol removal
in the human body. Strict regulation of both cholesterol and bile acid levels is
necessary to maintain a healthy balance and to prevent health problems. Bile acids are
natural ligands for famesoid x receptor (FXR), a nuclear receptor that controls gene
expression for multiple proteins involved in maintenance of bile acid homeostasis.
Many endogenous and exogenous chemical ligands have been found to activate FXR;
chenodeoxycholic acid (CDCA) is the most well characterized endogenous ligand.
This study identifies a synthetic indole-acetamide, FGIN-1-27, as a new FXR agonist.
FGIN-1-27 is already a known ligand of the translocator protein 18 kDa (TSPO), a
mitochondrial cholesterol transporter.

FXR regulates target gene transcription through binding to special inverted repeat-I
(IR-1) consensus DNA elements. Ligand binding to FXR was measured by inserting
an IR-1 sequence upstream of a firefly luciferase detector gene that increased
transcription of luciferase pr:oportional to ligand binding in a human hepatoma cell
line (HuH-7). Results show that FGIN-1-27 is a partial agonist of FXR that activates
FXR alone at 10 µM, but decreases activation from CDCA at 100 µM when cotreated.
Two other well-known ligands of TSPO, FGIN-1-43 and PKl 1195 were investigated
also for their effects on FXR mediated transcription. Both compounds acted as
antagonists, decreasing the activity of CDCA (100 µM) while showing no activation
of FXR alone at 1O µM treatment.

Agonist ligand binding to FXR increases the expression of the target gene, bile salt
export pump (BSEP), and another nuclear receptor, small heterodimer partner (SHP).
Through real time RT-PCR DNA amplification of both genes, we found FGIN-1-27
treatment in HuH-7 cells and primary human hepatocytes increased both BSEP and
SHP gene expression. Additionally, expression of cholesterol 7a-hydroxylase
(CYP7 Al), an enzyme involved in bile acid synthesis, is negatively regulated by FXR;
we show that FGIN-1-27 decreased the expression ofCYP7Al.

In addition to in vitro studies, we investigated in silica molecular modeling of the
binding of these TSPO ligands to FXR and demonstrated that these synthetic
compounds fit into the ligand-binding pocket of FXR with favorable energy
measurements. We identified key amino acids involved in agonist ligand binding in
silica, and through mutation assays we confirmed that H447 is the major amino acid
responsible for FXR interaction with an agonist ligand.

Taken together, FGIN-1-27 binding to and modulating two of the proteins involved in
bile acid synthesis indicates there is overlap in the role of TSPO and FXR. FGIN-1-27
and related indole-acetamides may be potential therapeutic drugs beneficial to
populations with enzyme deficiencies that cause high cholesterol levels. Further
investigation of the role of mitochondria in bile acid synthesis will lead to a better
understanding of the regulation of cholesterol and bile acid homeostasis.
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1. INTRODUCTION

1.1 Cholesterol and bile acid homeostasis
Bile acids are natural emulsifiers of dietary lipids, cholesterol, and fat-soluble vitamins
(l). They are secreted into the small intestine and ultimately control the amount of
cholesterol that is absorbed from the diet. Accumulation of excess cholesterol in
circulation, due to deficiencies in enzymes of cholesterol catabolism, poor health and
diet, and other risk factors, can lead to atherosclerosis and coronary heart disease (2,3).
If the excretion of bile acids is hindered, the liver will accumulate these cytotoxic

substances that are normally effluxed to the gall bladder and eventually to the
duodenum, leading to cholestasis (4). The synthesis of bile acids must be tightly
regulated to maintain homeostasis between cholesterol and bile acid concentrations. In
adult human liver, approximately 500 mg of cholesterol is converted into bile acids
each day through multiple pathways involving 16 different enzymes (reviewed by
Russell (1)). About 95% of bile acids are re-circulated throughout the body before
returning to the liver, while the other 5% are removed from the body through fecal
matter. The biosynthesis of bile acids makes up about 90% of all cholesterol
catabolism, with the remaining 10% going to steroid hormone biosynthesis (1,5,6).

Bile acid synthesis occurs through two main pathways, the classic/neutral and the
alternative/acidic, each of which is initiated by a cytochrome P450 enzyme (CYP) 1
(extensively reviewed in (1,5,7-9)). CYP enzymes are a special gene superfamily

I
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responsible for the metabolism of multiple xenobiotic and endogenous compounds

(1O,11 ). Of the 57 human CYP genes, only seven take part in bile acid biosynthesis
(?). Six of the bile acid synthesis CYP enzymes are present on endoplasmic reticulum
of eukaryotic cells, the seventh being found only inside the inner mitochondrial
membrane (12). Nuclear receptors often regulate transcription of cytochrome P450
genes through negative feedback from accumulation of a substrate, such as bile acids
and oxysterols (13,14).

Most bile acids

(~90%)

are produced in the liver through the classic pathway, initiated

by the rate-limiting cholesterol ?a-hydroxy lase (CYP7 Al) microsomal enzyme that
converts cholesterol to 7a-hydroxycholesterol (1,15). The remaining 10% of bile acids
are synthesized through the alternative pathway initiated by mitochondrial sterol 27hydroxylase (CYP27Al) in extrahepatic tissues (16,17) or cholesterol 24-a
hydroxylase (CYP46Al) in the brain (18). The alternative pathway forms oxysterols
that must be further converted into bile acids through ?a-hydroxylation (19).
Cholesterol homeostasis must be maintained i~ the brain as in other tissues, but
cholesterol cannot readily cross the blood brain barrier. To overcome this problem,
CYP46Al produces 24S-hydroxycholesterol, an oxysterol that can cross the blood
brain barrier, and be further converted into bile acids in the liver via the oxysterol 7ahydroxylase (CYP39Al) (20). The CYP27Al-initiated pathway forms predominantly
27-hydroxycholesterol, which is 7a-hydroxylated by CYP7Bl (21). CYP27Al is
involved also in both pathways further downstream in ring modifications to oxidize
and cleave the sterol side chain (1, 19). The alternative pathway produces solely
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chenodeoxycholic acid (CDCA), while the classic pathway produces both CDCA and
cholic acid (CA) (8). The relative abundance of CA versus CDCA is ultimately
regulated by sterol 12a-hydroxylase (CYP8Bl) (7). Figure 1 illustrates both pathways
of bile acid synthesis in a condensed version showing only intermediates produced
directly by CYP enzymes.

Since strict enzymatic control is required to prevent bile acid or cholesterol
accumulation, mutations of CYP enzyme genes can have potentially drastic
consequences. CYP7Al and CYP27Al are two main CYP enzyme genes with
mutations most often associated with cholesterol metabolic diseases and conditions. A
homozygous mutation in CYP7A1 is associated with hypercholesterolemia, a
condition of high total cholesterol and low-density lipoprotein cholesterol (LDL-C)
concentrations accumulating in plasma, and accumulation of cholesterol in the liver
with limited bile acid synthesis or excretion (22-24). Studies have shown that 40-60%
of the Caucasian North American population are carriers of an A to C substitution
polymorphism in the CYP7Al promoter region producing a high LDL-C phenotype
with a recessive CYP7 Al -/- mutation that is more prevalent in men (23,25,26). Some
individuals with this substitution have been shown to be resistant to cholesterollowering 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors
and experienced premature gallstones from bile acid accumulation (23). It is
hypothesized that the inhibition of cholesterol synthesis by HMG-CoA reductase
inhibitors would not significantly decrease total cytosolic cholesterol concentrations,
therefore the increase in LDL receptor expression normally resulting from inhibition

4

of cholesterol synthesis, thus decreasing LDL-C in blood, would be limiting with little
effect on lowering LDL-C concentrations (23).

Lower than normal CA concentration is often an indicator of CYP7 Al deficiency as a
result of the classic pathway being absent with compensation by the acidic pathway
that produces only CDCA (22); typically the ratio of CA to CDCA is 2:1 (7,22). In the
event of this compensation, CYP27Al activity doubles preventing complete
deficiency of CYP7Al from being lethal (23). Components of the acidic pathway can
also be affected by mutations. Mutations that decrease CYP27Al expression or
activity lead to irregular cholesterol catabolism, and are involved in cerebrotendinous
xanthomatosis (CTX), an inherited syndrome of neurological problems and premature
atherosclerosis (27,28). The 40 known gene mutations that cause CTX are implicated
in the build-up of cholestanol (a sterol cholesterol derivative) in myelin sheaths in the
nervous system. If the disease is discovered early enough it is often treatable with oral
bile acid therapy (1 ,5).

1.2. Role of trans locator protein (18 kDa)
The acidic pathway is limited not by the initial enzyme CYP27A1 itself, but by the
delivery of cholesterol to CYP27 Al in the mitochondria (29). The transport of
cholesterol into the mitochondria occurs through the translocator protein 18 kDa
(TSPO), which is located predominantly on the outer mitochondrial membrane
(OMM) (30,31) in cells of the adrenal glands, lung, heart, liver, and multiple other
tissues (32). TSPO possesses five membrane-spanning domains that can form
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multimeric protein polymers able to bind endogenous ligands that facilitate cholesterol
binding (31,33). The polymer formation is facilitated by reactive oxygen species most
likely produced from the CYP enzyme activity inside the mitochondria (31 ). TSPO,
however, does not act alone and requires the assistance of steroidogenic acute
regulatory (STAR) protein (34) (Fig. 2). Through a complex pathway, cholesterol
binds to STAR in the cytoplasm for transport to the mitochondria (35), then STAR
binds to the OMM (36), where cholesterol can be transported to TSPO and mobilized
across the outer to the inner mitochondrial membrane. Binding of ligands to TSPO,
including the endogenous ligand, diazepam-binding inhibitor, allows cholesterol to be
transported into the mitochondrial, (37-39). Both endogenous and exogenous ligands
increase 27-hydroxycholesterol production, identifying the availability of cholesterol
to CYP27Al as the rate-limiting step in the alternative pathway (40).

1.3 Role of nuclear receptors
In high concentrations, bile acids can be toxic, so the potential toxicity is regulated by
negative feedback (41 ). Bile acid synthesis is reduced in the presence of high bile acid
concentrations, and conversely, low concentrations result in bile acid synthesis
activation to increase the bile acid pool (1). Bile acid feedback is regulated by nuclear
receptors that directly control target genes by activating or repressing transcriptional
activities. Typically, nuclear receptors have a DNA binding domain that recognizes
specific DNA sequences (hormone response elements) through a zinc finger region,
and a ligand-binding domain (LBD). The response elements are comprised of halfsites at least 6 base pairs long (typically AGGTCA) (42,43). Nuclear receptors bind to
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elements as either a homo/heterodimer to sequences of direct (DR) (-7-7),

everted (ER) (~-7) or inverted (IR) (-7~) repeats spaced by 1-5 nucleotides, or as a
monomer, binding only to a half site (44 ). Helix 12 of the LBD is a ligand dependent
activation function-2 (AF-2) domain, which upon agonist ligand binding to the
receptor will recruit a coactivator protein with acetyltransferase activity (43).
Acetylation of residues on histone proteins causes relaxation of the chromatin
structure so the transcriptional machinery can gain access to the DNA to increase gene
transcription (45).

The endogenous bile acid receptor, famesoid x receptor (FXR; NR1H4), a member of
the nuclear receptor superfamily (46), is a good potential target for pharmacological
therapy to regulate bile acid concentrations, and thus cholesterol concentrations. FXR
forms an exclusive heterodimer with retinoid x receptor a (RXRa; NR2Bl) (47) (the
heterodimer formation occurs independent of ligand and DNA binding, but it is
necessary for FXR receptiveness to bile acid ligand binding (47,48)). Multiple studies
show that the primary and secondary bile acids: CDCA, lithocholic acid, and
deoxycholic acid, are endogenous ligands of FXR, which in tum regulate bile acid
homeostasis through transcriptional effects on specific genes (49-51 ). The most potent
endogenous ligand of FXR is CDCA (50,51) and CDCA binding to FXR recruits the
steroid receptor coactivator-1 (SRC-1) to the LBD (46,50,51 ). Along with bile acids,
potent exogenous ligands of FXR have been made, including the potent synthetic
agonists GW4064 (52), fexaramine (53) AGN29 and AGN31 (54). Additionally,
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guggulsterone, a compound isolated from the guggul tree traditionally used m
Ayurvedic medicine, is a natural antagonist of FXR (55).

Agonist ligands of FXR play a major role in feedback regulation of bile acid synthesis.
FXR can indirectly repress CYP7 Al expression through an FXR-activated small
heterodimer partner (SHP; NROB2) pathway (56). FXR binds to an IR-1 repeat on the
promoter region of SHP increasing SHP transcription and expression (57). SHP then
interacts with other nuclear receptors, either liver receptor homolog-1 (LRH-1;
NR5A2) (58,59) or hepatic nuclear factor-4 (HNF4; NR2Al) (60), by competing for
coactivators, recruiting corepressors, or through its own intrinsic corepressor function
(61 ). LRH-1 binds as a monomer to the promoter region of CYP7A1 gene (5 ' TCAAGGCCA-3') (56,62), while HNF4 binds as a homodimer to a DR-1 response
element (5'-TGGACT T AGTTCA-3') (63). FXR is known also to increase bile acid
efflux from the liver. FXR binds to an IR-1 repeat (5'-GGGACA T TGATCCT-3') on
the promoter region of the gene for bile salt export pump (BSEP), an ATP-mediated
receptor on the bile canaliculi, increasing its expression (64). The liver specific BSEP
is the principal bile acid efflux transporter that pumps bile acids against a strong
concentration gradient out of the liver; precise control of this receptor is essential for
maintenance of bile acid homeostasis (65,66).

In most cases, agonist activation of FXR should lower cholesterol up-take by
diminishing the liver bile acid pool through increased efflux and through inhibition of
CYP7Al activity, thereby inhibiting cholesterol absorption in the intestine (67).
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r thl.s is not always the case since FXR agonists would show little effect in
Howeve,
people lacking functional CYP7Al enzymes. Also, CYP27Al is not a rate-limiting
so bile acids and their intermediates have less effect on this pathway in
enzyme,
comparison to CYP7Al; agonist effects of FXR through bile acids typically do not
regulate transcriptional activity of CYP27A1 directly (68,69). Individuals with poor
synthesis via the classic pathway, therefore, may therapeutically benefit from relevant
and useful targets of TSPO as a modulator of the alternative pathway.

1.4. TSPO and FXR interplay
It is possible that many of the known ligands of TSPO could additionally regulate the

cholesterol turnover rate by acting upon other receptors. Since both mitochondrial and
nuclear receptor signaling pathways are involved in maintenance of bile acid
homeostasis, this study was designed to investigate the interplay between TSPO and
FXR by demonstrating TSPO ligands modulate FXR activity also. PKl 1195, one of
the most well known and widely used ligands of TSPO, is known to increase the
cholesterol binding rate to the protein (31,70,71). Similarly, a series of 2-aryl-3indoleacetamides (named FGIN-1), designed by Romeo et al. (72), selectively bind to
TSPO (73,74). The aim of this study was to investigate binding of PKl 1195 and
FGIN-1 compounds to modulate FXR target genes and to provide evidence of binding
pocket interactions with these compounds. We have found that FGIN-1-27 is a partial
agonist of FXR that activates downstream transcription of FXR target genes, as
demonstrated in both optimized luciferase assays and measurements of endogenous
gene expression in liver cells. We show that FGIN-1-43 is a selective antagonist, able
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to block FXR agonist activation of FGIN-1-27 but is less inhibitory of CDCA
activation of FXR. PKl 1195, on the other hand, is a non-selective FXR antagonist.
Through in vitro transcriptional and mRNA expression studies and in silica molecular
modeling studies we show that each of these compounds binds directly to the FXR
LBD. Activation of both TSPO and FXR with one compound is favorable for dual

maintenance of bile acid and cholesterol homeostasis.
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2. EXPERIMENTAL PROCEDURES

2. l. Chemicals and biochemicals
COCA (sodium salt) was purchased from Sigma-Aldrich® (St. Louis, MO). FGIN-127, FGIN-1-43, and PK11195 were purchased from Tocris Bioscience (Ellisville,
MO). Dimethyl sulfoxide (DMSO), used as a negative control with all treatments, was
purchased from Fisher Scientific (Pittsburgh, PA). The y-aminobutyric acid (GABA)ergic ligand library (version 3.6, lot# N1205) was purchased from Biomol (now Enzo

Life Sciences, Plymouth Meeting, PA). Cell culture media and additives were from
Invitrogen/GIBCO Corp. (Carlsbad, CA) or Lonza (Hopkington, MA).

2.2. Plasmid constructs
Consensus FXR response element (FXRE) (75) contained four copies of the IR-1
sequence (underlined) 5'-ACAAGAGGTCATTGACCTTGTCC-3'. Forward and
reverse oligonucleotides of the IR-1 sequence were annealed and blunt-end ligated
into the Sma I site of luciferase vector pTK-Luc. To make pTK-Luc, pGL3-Basic
vector (Promega, Madison, WI) was cut with Bglll and blunted with T4 polymerase. A
DNA fragment ( 165 bp) containing the core thymidine kinase (TK) promoter was cut
from vector pBLCAT2, blunted with T4 polymerase and ligated into pGL3 vector
maintaining the original multiple cloning site. Original pTK-Luc and FXRE-TK-Luc
cloning was performed in the laboratory of Dr. Curtis Omiecinski (The Pennsylvania
State University, State College, PA). Expression plasmids for FXR were produced in
pcDNA3. l vector (Invitrogen/GIBCO), p3XFLAG vector (Sigma Aldrich) and pM
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D Bioscience San Jose, CA). Human liver cDNA was subjected to PCR
vector (B
'
amplification

of

FXR

gene

us mg

gene-specific

pnmers

CGCGGATCCTAGCCGCCATGGGATCAAAAATGAATCTC-3'

and

(FP:
RP:

5'-

5' -

GCTCTAGATCACTGCACGTCCCAGATTTCA-3'); primers were designed to
amplify cDNA coding for the full 472 amino acid FXR sequence (NM_005123). FXR
PCR product and vector were separately digested with BamHI and Xbal before being
combined for ligation. For a mammalian two-hybrid assay, the reporter vector, pFRLuc, containing five copies of an upstream activation sequence (UAS) that binds to
GAL4 protein (76), was cloned upstream of the firefly luciferase gene. pVP16-FXR
contained the full-length FXR cloned downstream of, and fused to, VP16 activation
function. GAL4-containing plasmid pM-SRC-1 was made by PCR amplification of
SRC-1 sequence coding for amino acids 570-780 (contains one of the receptor
interacting domains (RID)) using the following primers, based on gene accession
number NM 003734: FP:

5'-GATCGAATTCCCTAGCAGATTAAATATACAA

CCAG-3' and RP: 5 '-GATCTCTAGATCACATCTGTTCTTTCTTTTCCACTT-3 '.
PCR-amplified product was digested with EcoRI and Xbal for cloning into pM.

2.3. Cell culture
HuH-7 cells (JTC-39), a differentiated hepatoma cell line, were originally from
Okayama University JCRB Cell Bank and kindly provided by Dr. Ruitang Deng,
University of Rhode Island, Kingston, RI. COS-I cell line (African Green Monkey
kidney cells transformed with Simian Virus 40) and ZR-7 5 (breast cancer cell line)
were obtained from American Type Culture Collection (ATCC, Manassas, VA). HuH-
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7 and COS-1 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)
ented with 5% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1%
suppIem
Glutamax, and 0.15% sodium bicarbonate, 1% sodium pyruvate, 10 mM HEPES
buflier, and 1% non-essential amino acids (Invitrogen/GIBCO). ZR-75-1 cells were
maintained in RPM! 1640 medium with 10% FBS and the same concentrations of
additives as for DMEM. Additionally, primary human hepatocytes were obtained from
an NIH-funded liver tissue cell distribution system (LTCDS) through Dr. Steven

Strom at the University of Pittsburgh (Pittsburgh, PA). The human hepatocytes were
seeded onto collagen type IA-coated culture plates and maintained with Williams'
Media E medium supplemented with isulin-transferrin-selenium (ITS+) solution, 100

nM dexamethasone, linoleic-bovine serum albumin conjugate, penicillin/streptomycin
and L-glutamine additives (77). Hepatocyte maintenance medium was changed every

other day and experiments were performed within 1-2 weeks after cell arrival to the
lab.

2.4. Transient transfections
2.4.1. HuH-7 transfe ctions with FXRE response element
T2s flasks of HuH-7 cells were transiently transfected with 5 µg of p(FXRE)4-TK-luc

reporter plasmid and 0.5 µg of Renilla luciferase expression plasmid (pRL-CMV)
(Promega),

using FuGeneHD

transfection reagent (Roche,

Brandford, CT),

Lipofectamine2000 transfection reagent (Invitrogen/GIBCO) or Polyethylenimine
(PEI) with an average MW of 25 kDa (Polysciences, Inc, Warrington, PA); a lmg/mL
stock solution of PEI was made in 20 mM HEPES buffer. The following transfection
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ios (µL reagent: µg DNA) were used for each type of transfection:
reagent rat
fuGene HD

(3 ·1) Lipofectamine2000 (3.5 :1), or PEI (4:1). Transfections were
· '

perfonned in serum-free media for 6-24 hours. In addition to the reporters, 1.25-2.5 µg
of emerald green fluorescent protein (pEGFP-Cl) (Clontech, Mountain View, CA) was
transfected into the cells to monitor transfection efficiency. Transfected HuH-7 cells
were then trypsinized and re-seeded into a 96-well plate and treated for 24 hours. The
60 GABA-ergic compounds (Table 1) were screened using single-well treatments.
Cotreatments of CDCA with FGIN-1-27, FGIN-1-43, and PKl 1195 were balanced
with equal amounts of solvent control, DMSO. Luciferase activity was measured using
Dual-Glo Luciferase Reporter kit (Promega) on a GloMax 96 Microplate
Luminometer (Promega). The luminescence from the firefly luciferase was normalized
to the Renilla luciferase luminescence to control for transfection efficiencies and for
well-to-well variation in cell numbers. The ratios of the measurements were calculated

and reported as mean fold change relative to DMSO (control) ± standard error of the
mean (SEM) (when greater than two replicates were performed).

2.4.2. Exogenous FXR expression
For exogenous expression ofFXR in HuH-7 and ZR-75-1 cells,1.25 µg of3 .1-FXR
was transfected along with p(FXRE)4 -TK-luc, Renilla, and pEGFP-Cl. As a control,
cells were also transfected with 1.25 µg of pcDNA3 .1 (+) empty vector in place of 3 .1-

FXR.
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2.4.3.

Mammalian two-hybrid assay

r 25 flas ksof COS-1 cells were transfected with 5 µg pFR-Luc reporter plasmid, 1.5 µg
of pM-SRC-1 construct, 1.5 µg of VP16-FXR LBD, 0.5 µg pRL-CMV, and 1.5 µg
pEGFP-Cl. Transfected COS-1 cells were trypsinized then re-seeded into 96-well
plates, treated, and luminescence measured using Dual-Glo, as described in section

2.4.l.

2.4.4. FXR Mutants

Point mutations of single amino acids of FXR, generously provided by Dr. Ruitang
Deng, were formed using a QuikChange site-directed mutagenesis kit (78,79). The
mutation sequences are listed in Table 2. ZR-75-1 cells were seeded into 6-well plates
and transiently transfected with 1 µg p(FXRE)4-TK-luc, 100 ng pRL-CMV, 200 ng
pEGFP-Cl, and 500 ng of 3 .1 (+), 3 .1-FXR, or hFXR mutant per well. The cells were
trypsinized and each well of a 6-well was re-seeded into a portion of a 96-well plate,
treated for 24 hours and read on the Microplate Luminometer, as described in section

2.4.1.

2.5. Real-time RT-PCR
HuH-7 cells were seeded into 12-well plates and each well was treated with a different
compound for 24 hours. Similarly, the human hepatocytes were obtained in 12-well
plates and treated after 4-6 days of routine maintenance. Following the protocol from
lnvitrogen/GIBCO, total RNA was harvested from the cells using TRizol reagent. The

RNA was reverse transcribed into cDNA using a High Capacity cDNA Reverse
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. t' n kit (Applied Biosystems, Carlsbad, CA). cDNA was subjected to generranscnp 10

'fi

spec1 1c a

mplification of FXR target genes using SYBR Green PCR Master Mix

(Applied Biosystems). Reactions were made 50 µL at a time with 25 µL of 2x SYBR
Green PCR master mix, 21 µL of nuclease free water, 1 µL each of the 10 µM forward

and reverse primers, and 2 µL of cDNA (4 ng/µL). The actin, BSEP, CYP7Al, FXR,

HNF4a, and LRH-1 primers were from Eurofins MWG Operon (Huntsville, AL), and

RXRa primers were from Integrated DNA Technologies (Coralville, IA) (see
sequences in Table 3). Each 50 µL reaction was split into 2 wells in a 96-well plate to
provide technical replicates. RT-PCR SYBR Green amplification was performed using
a 7500 Real-Time PCR System from Applied Biosystems with thermocycling as
follows: 2 minutes at 50°C, 10 minutes at 95°C, followed by 40 cycles of 95°C for 15
seconds and 60°C for 1 minute. All values were normalized to actin, due to its
ubiquitous and constant expression in all cells, and were reported as fold change
relative to mean DMSO (control)± SEM. Applied Biosystems v2.0 SDS software was
used for analysis; auto threshold and auto baseline settings were used to ensure that
the optimum analysis settings were used for all reactions. Threshold values were set in
the exponential phase of the change in normalized reporter dye fluorescence (~Rn).
The baseline of each sample was set to eliminate background noise from the
measurements.

2.6. Molecular modeling
To further investigate the docking of compounds in the LBD of FXR, in silica
molecular modeling with Scripps Research Institute's (La Jolla, CA) AutoDock v4.2
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was perfiorm

ed on CDCA, PKl 1195 and several FGIN-1 compounds. The crystal

FXR was obtained from the Protein Data Bank (PDB.org) (PDB ID code
structure of

3BEJ) (80). The structure had 237 residues (amino acids 235-472) of the LBD
crystallized with Merck FXR agonist # 1 (MF A-1) that occupied the pocket in an
active conformation, with a small fragment of SRC-1 (residues 676-700) that was
bound to the AF-2 domain (helix 12) of FXR. The coordinates for residues 235-243
and 472 of FXR were missing and not accounted for.

Using Discovery Studio Visualizer v2.5 (Accelrys, San Diego, CA) the protein crystal
structure was inspected and cleaned of any misplaced or misinterpreted atoms. Polar
hydrogens were added to each amino acid to complete the valance of each atom (nonpolar hydrogens were implied). The valence of charged amino acids was adjusted so
the overall charge on each residue was an integer, e.g. the guanidine group on arginine
was given two hydrogens per nitrogen so a neutral charge resulted. Since the protein
was only a portion of FXR, the end residues were adjusted to mimic the N-terminal
and C-terminal for the purposes of docking. The ·N-terminal nitrogen of Glu244 was
allowed two hydrogens to make a + 1 charge and the C-terminal Val4 71 was given a
hydroxyl group to complete the carboxylic acid to make a -1 charge. These changes
allowed the polar hydrogens and gasteiger charges to be added to the protein without
errors in AutoDock Tools v4.2 (ADT). Polar hydrogens were added to the 3D
coordinates of the ligand chemical structures generated from SMILES strings in
Discovery Studio. One of the main advantages of AutoDock was that full ligand
flexibility was possible for docking to static or partially flexible macromolecules (81 ).
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for compo

unds in this study, the number of torsions were as follows: FGIN-1-27,

FGIN-l-43 , FGIN-1-51 all had 14 torsions, FGIN-1-20 had 8 torsions, PKl 1195 had 5
.
and CDCA had 7 torsions. A grid box was positioned over the ligand-binding
torsions,
pocket with a box size of 50 x 36 x 36 with one grid unit equal to 0.375

A. Map files

were formed for each atom type within the ligand (all contained different heteroatoms

O, F, Cl, N) with the FXR LBD structure using AutoGrid. This file contained the
position characteristic of every atom so the grid map calculations were represented for
each ligand.

Each ligand was started in a random position within the grid box. The Lamarckian
genetic algorithm parameters were as follows: genetic algorithm (GA) runs (100 or

200), population size (150), maximum number of evaluations (2,500,000), and
maximum number of generations (27,000). The local search parameters were as
follows: number of local search runs (50), maximum number of iterations (300), and
probability of any particular phenotype being subjected to local search (0.01 ). To
allow for accurate energy calculations, the number of evaluations must increase for the
number of ligand torsions. Increasing the number of GA runs with 2,500,000
evaluations per run allowed for more accurate calculations. Due to computational
constraints, the GA runs were performed 100 or 200 runs at a time, 800 total for the
FGIN-1 compounds and 600 total for CDCA and PKl 1195, the resulting docking log
files were then combined by opening groups together in ADT and reclustering at 2.0 A
root-mean-square (RMS).

Clusters containing fewer conformations than the

detennined rand
b
.
.
om num er value were disregarded (calculat10n: # GA runs I # of
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_ ndom value). Therefore, clusters that contained very few conformations
clusters - ra
.kely formed by random chance. Average binding energies for each cluster
were more 11
~

ed at random were calculated and graphed as histograms. The conformations

not 1orm

with the lowest binding energies were evaluated for possible hydrogen bonding using
Discovery Studio's hydrogen bond monitor default parameters. Additionally, van der
Waals interactions were measured using the intermolecular neighbor monitor in
Discovery Studio. The distance between atoms in each residue and each ligand were
further analyzed. The van der Waals interactions were calculated by addition of the
radii of atoms in the ligand and surrounding amino acid atoms with the following radii
values: carbon-1.87 A, nitrogen-1.50
1.47 A, chlorine-1.75

A,

oxygen-1.40

A,

hydrogen 1.10

A,

fluorine-

A, and sulfur-1.85 A.

2.7. Statistical analysis
Individual values of luciferase assay replicates were analyzed using Student's t-test.
The mean, SEM, n values were used to determine significance of RT-PCR values also
using Student's t-test. A Grubbs' outlier test was .used on all replicate values prior to
mean calculations. Differences were deemed statistically significant differences where
pS0.05.
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3.RESULTS

3. 1

TSPO ligands bind also to FXR

J.J.1 GABA-ergic library screen
Since many chemical compounds bind to both GABA receptors and TSPO, we
screened a GABA-ergic chemical library (compounds are listed in Table 1), which
contained specific TSPO ligands (F series), to examine the overlapping involvement
of TSPO ligands binding also to FXR. In this screening assay, agonist ligand binding

to FXR drove the expression of an IR-1 regulated luciferase reporter gene. In the
library screen (Fig. 3A), one compound, F2 (FGIN-1-27), increased luciferase
expression considerably compared to the control. This increase was similar to that
observed with CDCA treatment. Conversely, two compounds structurally similar to
FGIN-1-27 that are TSPO ligands also, FGIN-1-43 (F3) and PK11195 (FlO), did not
increase luciferase expression. Since the FGIN-1 compounds were previously shown

to be a selective ligand of TSPO (73,74) and PKl 1195 is a known ligand (31,70,71),
these compounds were still included in further experiments for comparison. The
chemical structures of the FGIN-1 compound contain the same 2-aryl-indole-3acetamide backbone with varying halide substitutions and hydrocarbon tail lengths.
PK11195 has similar aryl ring structures to the FGIN-1 compounds with chlorine on
the phenyl ring. These compounds are quite structurally different from CDCA as seen

in Figure 3B (the carbons of CDCA are numbered to correspond with the text).
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3.12
..

Coactivator recruitment

. d' tor that a compound is a ligand of a nuclear receptor is their ability to

One m 1ca

.
activators.
recruit co

In

the

presences

of an

agonist

ligand,

the

histone

acetyltransferase, SRC-1, is recruited to the LBD of FXR (82,83). To further validate
that these compounds bind to FXR, a mammalian two-hybrid assay was used to
demonstrate coactivator recruitment to a ligand-activated FXR (Fig. 4). CDCA at 10

µM and 100 µM significantly increased luciferase expression compared to the control,
signifying coactivator recruitment. Similarly, FGIN-1-27 at 5 µM and 10 µM also
significantly recruited SRC-1 to the LBD. FGIN-1-27 displayed maximum agonist
activity at 5 µM - 10 µM. Interestingly, PKl 1195 significantly decreased luciferase
expression compared to the control, indicative of decreased basal SRC-1 recruitment.

3.2. HuH-7 hepatoma cell line expresses endogenous FXR
Human hepatocytes are the ideal cell type for in vitro studies of liver pathology and
physiology studies, but cannot be easily obtained in large numbers because of limited
availability of healthy donors. Therefore, we examined two cell lines as alternatives to

primary hepatocytes. Our results showed that the HuH-7 cell line expressed similar
amounts of endogenous FXR mRNA compared to human hepatocyte case HH1498

(Fig. 5A). ZR-75-1 breast cancer cell line, on the other hand, expressed very little

FXR compared to HH1498 . ZR-75-1 was chosen as a good cell line to use for FXR
over-expression studies that required limited endogenous FXR interference. All cell
lines tested expressed similar amounts of RXRa, with no significant difference
compared to HH1498. HuH-7 cells expressed very little endogenous SHP but did not

21

lack LRH-1 or HNF4a expression (Fig. SB). In HuH-7 cells, both CDCA and FGIN-127 significantly increased IR-1 driven luciferase expression in the presence and
exogenous FXR (Fig. SC), while FGIN-1-43 did not modulate luciferase
absence Of
. ·ty There was a significant increase in luciferase expression when ZR-7S-1 cells

acttv1 .

were treated with CDCA and FGIN-1-27 in the presence of exogenous FXR (Fig. SD).
No change occurred from treatments in the ZR-7S-l cells in the absence of exogenous

FXR.

3.3. FGIN-1-27 is a partial agonist of FXR; PK1119S and FGIN-1-43 are antagonists
To further explore the binding of TSPO ligands to FXR, we examined the effects of
FGIN-1-27, FGIN-1-43 and PK1119S on CDCA-activated FXR. Figure 6 represents
the binding properties of these compounds in different combinations of treatments at
varying concentrations. As expected, CDCA and FGIN-1-27 increased luciferase
expression alone at all concentrations. Our study showed that FGIN-1-27 (10 µM),
FGIN-1-43 (10 µM) and PK1119S (10 µMand 1 µM) decreased luciferase expression
of COCA-activated FXR at 1OOµM. However, when CDCA was limiting (::S 10 µM),
FGIN-1-27 further activated FXR and exhibited an additive effect with CDCA. When
COCA was at 100 µM, FGIN-1-27 (10 µM) significantly decreased transcription,
acting as a partial agonist. Additionally, FGIN-1-43 (10 µM) antagonized CDCA at
100 µM and was not an agonist alone. When CDCA concentration was limiting,
FGIN-1-43 had no effect on CDCA-activated FXR; however, FGIN-1-43 (10 µM) did
decrease luciferase expression due to FGIN-1-27 agonist effects at 10 µMand 1 µM.
PK1l l95 (10 µM) decreased FXR activation by CDCA at 100 µM, 10 µM, 1 µMand
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100 nM. pKll 195 alone significantly decreased basal transcription levels at 1O µM.
.. lly PKll 195 at both 10 µM and 1 µM decreased FGIN-1-27-activated (1
Add1tiona ,

µM and 10 µM) luciferase expression.

J.4. Effect of compounds on genes downstream of FXR
3.4.1 Changes in BSEP and SHP expression

Another way to measure transcriptional effects of a compound on a nuclear receptor is
to look at regulation of specific downstream target genes. FXR ligands directly
increase transcription of downstream genes, including BSEP and SHP (84). In our
studies, FGIN-1-27 increased mRNA expression of both BSEP and SHP in human
hepatocytes (cases HH1486 and HH1498) and HuH-7 cells similar to levels seen with
COCA treatment, while FGIN-1-43 did not increase basal expression(Fig. 7 and 8).
Cotreatments of FGIN-1-43 or PKl 1195 with CDCA and FGIN-1-27 did not
significantly decrease BSEP mRNA expression in HH1498 (Fig. 7); however, similar
to the luciferase FXRE results in HuH-7 cells, FGIN-1-43 did significantly repress
BSEP and SHP expression induced by FGIN-1.:.27 ligand binding, but not CDCA.
PKll 195 did not repress CDCA or FGIN-1-27 induced BSEP mRNA expression in
HuH-7 cells or in HH1498 . Conversely, FGIN-1-43 and PKl 1195 increased SHP
mRNA expression when combined with CDCA in HH1498 (Fig. 8). PKll 195 also
increased SHP expression when combined with FGIN-1-27 in HH1498. In HH1498,
PKl 1195 alone increased mRNA expression of both BSEP and SHP.
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3.4.2.

Changes in CYP7Al expression

ownstream target gene of FXR is CYP7A1, though the gene is indirectly
Another d

regu lated ., COCA indirectly represses CYP7A1 expression through a SHP mediated
pathway (56). Results show that both COCA and FGIN-1-27 significantly repress
CYP7Al expression in human hepatocytes (Fig. 9). FGIN-1-43, on the other hand,
does not alter basal expression of CYP7 Al . Unfortunately, CYP7 Al expression
studies in HuH-7 cells yielded inconsistent results (data not shown), most likely due to
the low expression of SHP (Fig. 5B). In another study, we also showed that PKl 1195
significantly repressed CYP7Al expression in HH1498, but to a lesser extant than the
effects seen by COCA and FGIN-1-27 (Fig. 9).

3.5. TSPO ligands bind to the LBD of FXR
To further explore the capacity of PKl 1195 and 4 FGIN-1 compounds to fit into the

LBD of FXR, in silico molecular modeling was performed. Docking results verified
that these TSPO ligands could fit into an active conformation of FXR. The crystallized
structure of human FXR (PDB ID code 3BEJ) (80) was used as the template to study
the binding properties of COCA, PKl 1195, and 4 FGIN-1 compounds. This template

was among 9 crystallized structures of FXR in the PDB, all of which had a ligand and
coactivator bound, except for 1OSH, which lacked a coactivator. Although this
template has been used for other docking experiments (78), 1OSH also lacked a
significant portion of helix 3, and therefore was not an ideal candidate. Two of the
structures were isolated from rat FXR, differing from human FXR by only 12 amino
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. b t r r the purpose of this study, only human FXR was relevant. Of all of the
acids, u 1 0'
tallized structures, 3BEJ chain B was the most complete structure with the
human crys
lowest b-factors in the binding pocket, so it was the best choice. B-factors are a
measure of the disorder in the x-ray diffraction pattern caused by temperaturedependent vibrations, and so provide a measure of confidence in the accuracy of each
atom's coordinates. MFA-1 formed an active conformation in the crystal structure, cocrystallized with a 24 amino acid fragment of SRC-1 bound to helix 12 of FXR (80)
(Fig. 10). For each theoretical conformation generated by AutoDock, an estimate of
the free energy of binding was calculated by the following formula: [final
intermolecular energy (van der Waals, H-bond, desolvation energy + electrostatic
energy)]+ [final total internal energy] + [torsional free energy] - [unbound system's
energy]. The lower the free energy of binding, the more energetically favorable the
conformation.

3.5.1. Docking ofCDCA

CDCA was allowed to have seven rotatable bonds so only 600 GA runs were
necessary to reach a state of no further refinement. At 2.0 A RMS clustering restraints,
ADT formed eight conformational clusters with estimated free energy of binding
ranging from -10.43 kcal/mol to -8.51 kcal/mol. The majority of conformations fell
into two of the eight conformational clusters; the other 6 contained fewer
conformations than the random number value (600/8 = 75) so they were disregarded
from further analysis. The largest cluster contained 493 conformations with an average
b" d"
m mg energy of -9.75 ± 0.009 kcal/mol (conformation a). The second largest cluster
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bad 75 confonnations with an average binding energy of -9.45 ± 0.028 kcal/mol
c

(con10

nnation b) (Fig. 1 lA). Conformation a oriented the carboxyl group on C24 of

COCA near T288 to form hydrogen bonds (hydroxyl oxygen 2.39
hydrogen 1.88

A, hydroxyl

A, carboxyl oxygen 1.77 A). In a flipped orientation (conformation b),

the COCA carboxyl group hydrogen bonded to Arg331 (2.16 A) and the oxygen of C7
hydrogen bonded to H447 (2.20 A). Not surprisingly, CDCA in conformation a fit an
orientation similar to MFA-1 (Fig. 10), which is a CDCA analog with an additional
phenyl ring at C21 and a carboxyl group at C3 (80). Results show CDCA in both
conformations was able to form van der Waal interactions with 13 residues on helices

3, 5, 10/11 and 12.

3.5.2. Docking of FGIN-1-2 7

Although structurally quite different from CDCA, FGIN-1-27 is a very hydrophobic
molecule and also fit into the ligand-binding pocket of FXR with inhibition constants

in the nanomolar range. From 800 GA runs, where free energy of binding ranged from
-10.23 kcal/mol to -5.80 kcal/mol, ADT formed 102 conformational clusters at 2.0

A

RMS clustering restraints, 77 of which contained fewer conformations than the
random number value (800/102 = 7.8), so were most likely reflected background
noise. Although AutoDock 4.2 allows flexible ligand docking to bind to a fixed
protein, increasing ligand flexibility (> 1O torsional degrees of freedom) decreases
consistency of the conformation clusters (81). FGIN-1-27 was fully flexible with 14
torsional bonds that rotated freely, compared to CDCA, which only had seven. This, in
part, explained the greater number of clusters generated despite the greater number of
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GA runs.

Closer inspection of the conformational clusters revealed that many clusters

·milar positions of the core ring structure, with the majority of variations
shared s1
between

Clusters

being accounted for by the numerous positions adopted by the

flexible hydrocarbon tails. For the FGIN-1 compounds, additional analysis was
performed to identify four major conformations based upon position of the core ring
structure only. As seen in Figure 1 lB, of the 25 non-random clusters of FGIN-1-27,

41% represented conformation a, where fluorine formed a hydrogen bond with T288
(I.97 A). One study showed that fluorine attached to an aromatic carbon can form a
hydrogen bond when the protein's donor atom is at an average distance of 2.698 A

(85). 20% of the clusters (conformation b) positioned fluorine close enough to
hydrogen bond to Y369 (2.44 A). The other two conformations (20% c and 18% d)
oriented the rings perpendicular to the pocket. Similar to CDCA, FGIN-1-27 was most
likely held in place in the LBD by van der Waals interactions with 16-18 residues on
helices 3, 5, 6, 7, 10/11, and 12.

3.5.3. Docking of FGIN-1-20

Analogs of FGIN-1-27 were also docked into FXR to examine the significance of
fluorine and the hydrocarbon tails to the binding properties. When the hydrocarbon
tails were shortened from hexyls to propyls in FGIN-1-20 (Fig. 11 C), the number of
torsions decreased by 6, resulting in fewer overall conformational clusters. From 800

GA runs of FGIN-1-20, free energy of binding ranged from -9.64 kcal/mol to -7.79
kcaVmol. ADT formed 35 conformational clusters at 2.0 A RMS clustering restraints,
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28 of which contained fewer conformations than the random number value (800/35 =

22. 9).

Similar to FGIN-1-27, fluorine in conformation a hydrogen bonded to T288

(l .94 A) but with an increased occurrence of 60%. The shorter tails limited FGIN-1-20

from fitting into conformation band favored conformation cat 34%. Additionally, the
oxygen in conformation c formed a hydrogen bond with H447 (2.14 A). FGIN-1-20
had lower average binding energies for each cluster compared to FGIN-1-27. No
conformationdwas formed. FGIN-1-20 still interacted with 13 amino acids of helices
3 5 6 7 and 10/11, which were most likely allowed for hydrophobic interactions.

' ' ' '

3.5.4. Docking of FGIN-1-51

The loss of the fluorine in FGIN-1-51 (Fig. l lD) caused no difference in orientation
compared to FGIN-1-27, and had a similar binding fingerprint. FGIN-1-51 was run
800 times and reclustered at 2.0

A

RMS clustering restraints forming 111

conformational clusters. Free energy of binding ranged from -10.44 kcal/mol to -6.52
kcal/mol. Of these 111 clusters, 24 contained fewer than the random number value
(8001111

=

7 .2) of conformations so they cannot be distinguished from background.

FGIN-1-51 favored conformation b and decreased the overall average binding
energies per cluster compared to FGIN-1-27 and FGIN-1-20. The absence of fluorine,
however, prevented FGIN-1-51 from forming hydrogen bonds with any of the residues

in the LBD.

3.5.5. Docking of FGIN-1-43

The structure of FGIN-1-43 differed from FGIN-1-27 only by lacking fluorine and
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. two chlorines. FGIN-1-43 also was allowed 14 torsions so 800 GA runs
possess mg
sary The range of free energy of binding values was much larger than for
were neees
·

any of the other FGIN-1 compounds, from -12.30 kcal/mol to -1.55 kcal/mol. From
first evaluations, 152 conformational clusters were formed; 116 contained fewer than
the random number value (800/152 = 5.3) of conformations so they were considered to

be background and unlikely to be significant. FGIN-1-43 in Figure 1 lE had similar
orientations to FGIN-1-27 but showed a greater range of binding energies overall and
the most variation within each cluster, creating larger SEM than the other FGIN-1
compounds. Despite the differences in binding energies, FGIN-1-43 only varied in
conformation from the other FGIN-1 compounds in conformation b because the
chlorophenyl ring did not fit close to Tyr369. Of FGIN-1-43's 36 clusters nonbackground clusters, 40% were in conformation c, 29% in conformation d and the
remaining 31 % split between conformations a and b. Even with the higher binding
energies, it is still theoretically possible for FGIN-1-43 to interact with 17 residues on
helices 3, 5, 6, 7, and 10/ 11 in an energetically favorable fashion.

3.5.6. Docking ofPKJ 1195
The most well known TSPO ligand, PKl 1195, was also docked into the LBD of FXR.
Since PKl 1195 only had 5 possible flexible torsions, fewer GA runs were required to
reach optimal refinement. Out of 600 GA runs ADT formed 9 conformational clusters
'

for PKl 1195 with free energy of binding ranging from -9 .94 kcal/mol to -8.81
kcaVmol. Of these 9 clusters, 8 contained fewer than the random number value of
conformations (600/9 = 66.7) so they were considered background binding. The
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1 ster contained 496 conformations represented by an average binding energy
largest cu
of-9.64 ± 0.005 kcal/mol. Figure 1 lF shows that PKl 1195 adopted only one possible
~ nnation within the pocket with no possibility or opportunity to form any
con10

hydrogen bonds, but was close enough to form hydrophobic interactions with 17
amino acids on helices 3, 5, 7, 10111, and 12.

3.5. 7. Mutational studies ofFXR

Since the molecular modeling studies were based on a fixed crystal structure, as
opposed to a fully flexible molecule in a biological environment, point mutations
formed in FXR were necessary to validate the studies. Only CDCA and FGIN-1-27
were examined due to their capacity to hydrogen bond. (Though FGIN-1-20 was also
able to form a hydrogen bond, this compound is not commercially available). Figure
12A shows the conformations of CDCA and FGIN-1-27 explained above. The

docking studies demonstrated that these compounds formed hydrogen bonds with
Thr288 (helix 3), Arg331(helix5), Tyr369 (helix 7) or His447 (helix 10/11), so single

amino acid mutations of these residues were fo~med (Table 2). Ser332 is the only
other residue in the pocket that could form hydrogen bonds with side chain atoms so a
mutation was also created for this residue as another potential key residue. As a
control, ZR-75-1 cells were evaluated with and without exogenous FXR to compare to
changes caused by mutated residues. In each mutation, the basal activation of FXR

was decreased compared to the wild-type FXR transfection. Both CDCA and FGIN-127 hydrogen bonded to T288 in silico; when threonine (T288L) was mutated,
activation by CDCA decreased to basal while FGIN-1-27 decreased by about half.
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Only COCA in conformation b hydrogen bonded to R331, so as expected, the arginine
mutation (R331L) prevented CDCA-induced expression, whereas FGIN-1-27 was not
affected. Conformation b of FGIN-1-27 hydrogen bonded to tyrosine 369, but Y369L
mutation resulted in a gain of function for FGIN-1-27. As expected, the Y369
mutation showed no change in CDCA. As predicted for CDCA in conformation b, the
histidine mutation (H447F) prevented luciferase expression. The H447F mutation
decreased activity also in response to FGIN-1-27. Even though no hydrogen bonding
was seen with Ser332, the mutation (S332F) decreased luciferase activity also with

both COCA and FGIN-1-27 treatments.
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4. DISCUSSION

FXR is involved in multiple aspects of the maintenance of bile acid homeostasis acting

as a mediator between bile acid synthesis and efflux from the liver (8). The alternative
pathway of bile acid synthesis requires TSPO for the trans location of cholesterol into
the mitochondria (29). Since both FXR and TSPO are important for maintaining bile
acid homeostasis, it is not improbable that a single compound modulates the activity
of each of these proteins. We first looked at a GABA-ergic chemical library in order to
identify chemical treatments, already known as TSPO ligands, that increase
transcription of an FXR-regulated luciferase reporter. We identified one compound,
FGIN-1-27, that activated FXR to a level similar to CDCA (Fig. 3A). FGIN-1-27 was
one of the specific TSPO ligands in the F series of compounds in the chemical library;
therefore, we chose two other structurally similar TSPO ligands (FGIN-1-43 and

PKl 1195) to investigate further.

Our studies show that FGIN-1-27 is a partial agonist of FXR (Fig. 6). We show
through in vitro luciferase reporter gene assays that treatment of FGIN-1-27 activates
FXR-mediated transcription but decreases FXR activation by CDCA when CDCA
concentration is not limiting (100 µM) . Even though the FXR ligand-binding pocket
preferentially binds amphipathic, non-planar bile acids that allow polar entities to form
hydrogen bonds with amino acid residues (86), FGIN-1-27 fits into this pocket also.
Based on the size of the pocket and of the individual molecules, it is unlikely that both

COCA and FGIN-1-27 bind to the pocket at the same time. According to in silica
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inolecuIarm

odeling results, FGIN-1-27 fits into the pocket with low binding energies,

comparabl e

to those of CDCA (Fig. 1 lA and 1 lB). Both CDCA and FGIN-1-27

hydrogen

bond to the same amino acid (T288) in silica, and show no FXR-activation

when H44 7 is mutated into phenylalanine (Fig. 12), which shows that both compounds
bind similarly inside the pocket and compete for binding positions. Because CDCA

bas more atoms that can form hydrogen bonds, compared to FGIN-1-27, CDCA can fit
into the binding pocket in more than one favorable position with more favorable
agonist binding. This is evident when CDCA (100 µM) is treated with FGIN-1-27 (10

µM); FGIN-1-27 antagonizes the effects of CDCA. However, when FGIN-1-27 and
COCA are both at 10 µM, FGIN-1-27 binding is the main factor contributing to the

increase in reporter gene transcription. Under normal circumstances, however, CDCA
concentration would rarely reach 100 µM, as seen in a study of bile acid
concentrations in the liver (87), where the average concentration of CDCA was 45 µM

(30 nmollg)2. Only with gallstone obstruction did the CDCA concentration reach 96
µM (64 nmol/g). Therefore, treatment with FGIN-1-27 in vivo would be predicted to
show only agonist effects on FXR.

In this binding study, CDCA fits into the FXR ligand-binding pocket, with 87% of the
possible conformations oriented so the C-24 carboxylate group hydrogen bonds with

Thr288 (Fig. l lA and 12A). The ?a-hydroxyl group of CDCA in the remaining 13%
of the conformations hydrogen bonds with H447 and the C-24 oxygen binds to

Arg3 3 t. In accordance with modeling studies performed by other groups, CDCA

2Th.
is calculation was based on a 1.5 kg adult liver
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.
.t elf similarly by positioning the 3a-hydroxyl group near His44 7, allowing the
onents is
C-24 carboxylate group to hydrogen bond to Arg331 (86), or it is oriented so the C-24
carboxylate oxygens hydrogen bond to Leu348 (78). The results of this study position
COCA (conformation a) in an orientation more similar to that typically adopted by
steroid hormones, and MFA-1, with the steroid rings rotated so that the 3a-hydroxyl
group is near Arg331 (Fig. llA).

It is possible that there is more than one functional orientation of CDCA in the LBD
that can cause agonist ligand effects from hydrogen bonding to more than one residue.
Our point mutation studies of FXR show that Thr288, Arg331 and His44 7 were the

key residues responsible for the agonist effects of CDCA (Fig. 12B), all of which
Conned hydrogen bonds in silica. This suggests that the ?a-hydroxyl and C-24
oxygens are key attributes for CDCA. Our studies are in agreement with other studies
that have shown the 3a-hydroxyl group, present on all bile acids, is not necessary for

FXR activation (86) and an oxygen in either a carboxyl group or an alcohol on C-24 is
responsible for the enhanced ligand potency (88). It is most likely a combination of the
hydrophobicity of CDCA and available oxygens to form hydrogen bonds that confers
agonist-binding properties, and allows CDCA to bind in more than one conformation.

Although the FXR ligand-binding pocket evolved to recogmze non-planar
amphipathic bile acids (86), FXR is able to bind compounds also with planar
components, such as the FGIN-1 compounds. All four FGIN-1 compounds subjected
to in silica modeling fit into four main conformations, a, b, c and d (Fig. 1 lB-1 lE).
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Alth ough

the orientations within the pocket are similar, the ranges of binding energies

vary among the FGIN-1 compounds. Since the FGIN-1 compounds have the same
corestruc

ture there may be no discrepancy in the initial recognition of the compound
'

by FXR, however, once inside the pocket differences in binding occur. Removal of the

fluorine from FGIN-1-27 (FGIN-1-51) did not inhibit binding inside the pocket of

FXR (Fig. llD). This suggests that the fluorine is not necessary for FGIN-1-27 to
enter the pocket, but it could still be responsible for its agonist effects. The fluorine in
FGIN-1-27 hydrogen bonded to Thr288 and Y369 in silica, however, mutational
studies show that Tyr369 is not responsible agonist effects of ligand binding of FGIN1-27 and Thr288 only decreased FXR-activity by about half. This discrepancy may be
due to the dimensions of the crystallized pocket formed by MF A-1 (Fig. 10), not truly
reflecting a biologically active flexible protein. The majority of the conformations of
all these compounds docked fit into an "L" shape configuration with the bottom of the
"L" pointing towards Thr288 . The phenol group on MF A-1 most likely formed an

additional crevice in the protein allowing ligands to bend when docked into the crystal
structure, even though the 3BEJ structure closely ·resembled that of a rat receptor
structure crystallized with 6-ethyl-CDCA (80). In a non-computerized environment
where the entire protein can be flexible, this pocket may not form with all ligands. In a
constantly flexible cellular environment, it is possible that the fluorine of FGIN-1-27

in conformation c could hydrogen bond to His44 7. This would correlate with the
mutation of His447 diminishing FXR-activation by FGIN-1-27 (Fig. 12B). Upon entry

into the pocket, it is conceivable that the FGIN-1 compounds would favor
conformations c or d and never bend into an "L" shaped conformation. When Arg331
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·nto Ieucine little change is seen in FGIN-1-27 activity compared with
is mutated l
'
wild-type FXR (Fig. 12B). If FGIN-1-27 was in conformation d, fluorine could
· ably hydrogen bond to the arginine, however, since Arg331 seems to have no
conce1v
significant interaction with FGIN-1-27, conformation c with the fluorophenyl group
near His447 is more probable. Although the mutation of Ser332 (S332F) eliminates
FXR-activation by treatments of both CDCA and FGIN-1-27, the addition of the
bulky phenylalanine residue is most likely large enough to block the entrance to the
binding pocket preventing any ligand entry.

To examine whether the hydrocarbon tails were factors in the binding of the FGIN-1
compounds, FGIN-1-20 was subjected to evaluation (Fig. llC). The original study
with the FGIN-1 compounds (72) found the binding affinity to TSPO increased with
increasing alkyl chain lengths, up to 6 carbons. In this study, however, decreasing the
number of carbons on the hydrophobic tails minimally changes the binding
orientations in conformations a and b, with little difference in binding energies.
However, the longer hydrophobic carbon tails in the other FGIN-1 compounds that
fold alongside the indole backbone in conformations c and d create hydrophobic
interactions favorable for ligand binding. The binding orientation changes when 3
carbons from each tail are removed; FGIN-1-20 does not fit into conformation d.
Additionally, the oxygen on FGIN-1-20 in conformation c forms a hydrogen bond
with His447. This orientation is unlikely to occur in structures with long hydrocarbon
tails, such as FGIN-1-27, because the tails would cause steric hindrance. We did,
however, see complete elimination of the agonist effects of FGIN-1-27 with the
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8447F mutation of FXR, but this correlates with earlier speculations that the FGIN-1
s may favor conformation c upon entry into the pocket with fluorine of
compound

FGIN-l-Z? hydrogen bonding to His44 7.

The addition of chlorine does not prevent FGIN-1-43 from fitting into the binding
pocket of FXR; instead, it only forms unfavorable binding energies (Fig. 1 lE). For
this compound, conformation c is favored most often. It is possible that the sheer size
of chlorine prevents FGIN-1-43 from binding efficiently. Interestingly, FGIN-1-43 is
better at antagonizing the agonist effects of FGIN-1-27 on FXR more so than with

COCA (Fig. 6). This suggests that FXR can recognize the core indole-acetarnide
structure without discrimination, but FGIN-1-27 has a higher binding affinity. When

both FGIN-1 compounds are present, both will go into the pocket, but FGIN-1-27 will
bind more favorably than FGIN-1-43. Similarly, because FGIN-1-43 does not bind to

any residues specifically, CDCA will bind more efficiently so FGIN-1-43 will be
displaced easier in the presence of CDCA. This idea also explains the antagonist
effects of PKl 1195 on both CDCA and FGIN-r-27. According to the modeling
results, PKl 1195 fits only into one orientation with an inhibition constant very similar

to CDCA (Fig. 11 F). Even though PKl 1195 does not interact with any residues
specifically, it is oriented so access to His447 is blocked. When PKll 195 is in the
presence of an agonist ligand, PKl 1195 could compete for occupancy of the pocket of

FXR and prevent CDCA or FGIN-1 -27 from binding (Fig. 6).
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tudies we had to take into account the possibility of the FGIN-1 compounds
'

In these S

binding to TSPO on the mitochondria to indirectly increase the synthesis of CDCA,
and in tum, activate FXR. In fact, FGIN-1-43 is found to be a more potent TSPO
ligand than FGIN-1-27 (72). Ifthere were any downstream effects present, FGIN-1-43
would show equal, if not more, activation of FXR than FGIN-1-27. In all of the
results, FGIN-1-43 never activates FXR, thus demonstrating FXR activation by FGIN-

1-27 is not a result of TSPO ligand binding.

We also show that FGIN-1-27 is as efficient as CDCA in recruiting the coactivator,
SRC-1, to FXR LBD (Fig. 4). At 10 µM, FGIN-1-27 binding causes greater fold
increase in luciferase expression than did CDCA treatment at 10 µM. The decrease in
capability of PKl 1195 to recruit SRC-1 correlates with this compound being an
antagonist. However, PKl 1195 does not antagonize BSEP and SHP expression as
expected (Fig. 7 and 8). In fact, cotreatment of PKl 1195 with CDCA and FGIN-1-27
shows either little change or an increase in BSEP and SHP expression in HuH-7 cells
and primary hepatocytes. Dussault et al (54) identified synthetic ligands of FXR that
are gene-selective and modulate SHP and CYP7 Al expression differently. The

discrepancy in PKl 1195 binding could be explained if the compound possesses
different antagonistic effects based on the target gene. It is also likely that PKl 1195
hinds to a number of different receptors. For example, in human hepatocytes,

PKl 1195 is an agonist of pregnane x receptor (PXR; NRl 12) and an inverse agonist of
co f .
ns Itubve androstane receptor (CAR; NR113), both also nuclear receptors (89),
although HuH-7 cells do not express detectable levels of either PXR or CAR. In
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I(

HH 1498, where SHP is not limiting, PKl 1195 treatment causes a significant increase
in SHP mRNA expression, but PKI 1195 does not inhibit CYP7 Al expression at the

I

same level as CDCA or FGIN-1-27 (Fig. 9). Our data shows PKl 1195 has little
· t effect on FXR alone, therefore, this increase in SHP expression and lack of
agoms

full CYP7Al repression could be due to PK11195 binding to LRH-1. If this were the
e
cas'

PKl 1195 could prevent SHP from binding to LRH-1, thus eliminating the

repressor function of SHP. Further studies of PKll 195 binding to LRH-1 to cause
direct transcriptional effects are necessary to validate this theory.

Jn these experiments, FGIN-1-27 proves to be at least equally as potent a ligand of

FXR as CDCA at 10 µM , despite inevitable variations between individual hepatocyte
cases. FGIN-1-27 increases both BSEP and SHP expression significantly, while
repressing CYP7Al expression, as expected (Fig. 7-9). FGIN-1-43 and PKl 1195
treatments, however, rarely cause any differences in gene expression from FXR
activation. With all data considered, we conclude that FGIN-1-43 is a selective
antagonist, competing only with the ligand with similar binding affinities to itself
(FGIN-1-27) and PKl 1195 is a non-selective antagonist.

In addition to showing that these TSPO ligands modulate FXR, we also investigated a
cell line with non-limiting endogenous FXR and RXR as an alternative to human
hepatocytes (Fig. 5). Although primary human hepatocytes are the best in vitro
representation of human liver, they vary among individuals and are expensive and
difficult to acquire and maintain. Therefore, HuH-7 cells are beneficial for FXR
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I

studies

Sl·nce

they can be cultured in large numbers and passaged repeatedly.

Unfortunately, HuH-7 lack SHP, so studies involving CYP7 Al repression through the
SHP pathway may be difficult. Additionally, we show that the breast carcinoma cell
. ZR 75-1 has very little endogenous FXR with non-limiting endogenous RXR.
bne,
'

Therefore, this cell line is ideal for mutational studies to avoid the interference of
endogenous FXR.

In summary, targeting the rate-limiting step in the alternative pathway would be
beneficial for upregulating this pathway. Correspondingly, TSPO ligands are known to
increase cholesterol uptake into the mitochondria, which has been proven to be the
rate-limiting step for the alternative pathway (29). Although controversial, some
studies have shown that bile acids do not regulate CYP27A1 expression the same as
CYP7Al (68,69), which is not surprising since increasing CYP27Al expression does
not affect bile acid synthesis rates (29). Therefore, upregulating the alternative
pathway apart from bile acid activation would be beneficial in people possessing
faulty genes for CYP7 Al because the alternative pathway is heavily relied upon.
However, in healthy populations an upregulation would not be necessary since the
alternative pathway contributes little to the overall synthesis (23).

We have shown that FGIN-1-27 increases FXR transcriptional activity to increase
BSEP and SHP expression. Also, FGIN-1-27 increases the rate of cholesterol entering
the mitochondria by binding to TSPO (72). As demonstrated in Figure 13, targeting
both TSPO and FXR with one compound would increase the bile acid synthesis rate of
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ative pathway while regulating homeostasis in the liver by controlling the
the altern
. feedback through FXR. This would occur by 1) FGIN-1-27 binding to TSPO,
negative
facilitating the transport of cholesterol into the mitochondria where 2) CYP27 Al
would initiate the production of COCA. Furthermore, 3) FGIN-1-27 binds to FXR to
4) increase BSEP expression that would increase the efflux of bile from the liver. As
bile acids are removed from the liver, the bile acid pool would decrease and trigger
more synthesis of COCA, thus lowering the cholesterol pool.

Future studies will be necessary to investigate the changes in the production of bile
acid intermediates following FGIN-1-27 treatment. Multiple other genes involved in
bile/lipid homeostasis are activated by FXR, including phospholipid transport protein,
intestinal bile acid binding protein, and multidrug resistant protein 2 (MRP2) (84). The
regulation of these genes by FGIN-1-27 should be investigated to further characterize
FGIN-1-27 as a potential therapeutic drug. Similarly, the liver x receptor (LXR;
NR1H3) increases expression of CYP7Al from increased oxysterol production in the
alternative pathway (90), thus regulating cell cholesterol concentrations. It would be
necessary also to explore the transcriptional effects of FGIN-1-27 on LXR. Overall, a
better understanding of the involvement of the mitochondria and FGIN-1-27 (and
related compounds) in nuclear receptor signaling will lead to possible therapies for
individuals with hindered bile acid synthesis.
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6. ABBREVIATIONS

ADT: AutoDock tools
Af-2: activation function-2 domain
BSEP: bile salt export pump
CA: cholic acid
CDCA: chenodeoxycholic acid
COS-1 : African Green Monkey kidney cell line transformed with Simian Virus 40
CTX: cerebrotendinous xanthomatosis
CYP7 Al: cholesterol 7a-hydroxylase
CYP7Bl: 25-hydroxycholesterol 7a-hydroxylase
CYP8Bl: sterol 12a-hydroxylase
CYP27Al: sterol 27-hydroxylase

I
I

CYP39Al: oxysterol 7a-hydroxylase
CYP46Al : cholesterol 24a-hydroxylase
DMEM: Dulbecco's Modified Eagle Medium
DMSO: dimethyl sulfoxide
DR: direct repeat
ER: everted repeat
FBS: fetal bovine serum
FGIN-1: 2-aryl-3-acetamide compounds from Fidia-Georgetown Institute for the
Neuorsciences (72)
FGIN-1-20: N, N-di-n-propyl 2-(4-fluorophenyl) indole-3-acetamide
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II

FGIN-1-27: N, N-di-n-hexyl 2-(4-fluorophenyl) indole-3-acetamide
FGIN-1-43: N, N-dihexyl 2-(4-chlorophenyl) 5-chloroindole-3-acetamide
FGIN-1-51: N, N-di-n-hexyl 2-(4-phenyl) indole-3-acetamide
FXR: famesoid x receptor
fXRE: FXR response element
GA: genetic alorithm
GABA: y-aminobutryic acid
HH1486: human hepatocyte case #1486
HH1498: human hepatocyte case #1498
HMG-CoA: 3-hydroxy-3methylglutaryl-coenzyme A
HNF4: hepatic nuclear factor-4
HuH-7: human hepatoma cell line
IR: inverted repeat
LDL-C: low-density lipoprotein cholesterol
LBD: ligand binding domain
LRH-1: liver receptor homolog-1
MFA-I: Merck FXR agonist #1 (17~-(4-hydroxybenzoyl) androsta-3, 5-diene-3carboxylic acid)
OMM: outer mitochondrial membrane
PKI 1195: 1-(2-chlorophenyl)-N-methyl-N-(1-methylprolyl)-3-isoquinoline
carboxamide
PDB: protein data bank

RMS: root-mean-square
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R)(Ra.: retinoid x receptor
SHP: small heterodimer partner
SRC-1: steroid receptor coactivator-1
STAR: steroidogenic acute regulatory protein
TK: thymidine kinase
TSPO: translocator protein (18 kDa), formerly known as peripheral-type
benzodiazepine receptor (PBR) (91)
UAS: upstream activation sequence
ZR-75-1: breast cancer cell line
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7. FIGURE LEGENDS
.

1. CYP enzymes involved in the two pathways of bile acid synthesis.
~ initiates t~e classic/neutral pathway to produce_ ~~olic acid (_CA) ~~d
h odeoxycholic acid (COCA). CYP27Al and CYP46Al mittate alternative/acidic
c ~~way forming oxysterols that must undergo ?a-hydroxylation before becoming
roCA. The carbons on cholesterol are numbered to correspond with the names of
h intermediate formed by each CYP enzyme shown (boxed); changes to each
::cture are illustrated in red. Note: other non-CYP enzymes are also involved in
these pathways.
Figure 2: The role of STAR and TSPO in cholesterol transport into the
mitochondria. Intracellular cholesterol binds to STAR, and through a complex
pathway involving other proteins not shown, cho.lesterol _is !ranspo:t:ed to the OMM.
Cholesterol is then transferred to TSPO where ligand bmdmg facilitates cholesterol
uptake into the IMM whe~e CYP27 Al resi~es. ~holesterol_ transport i~ the ratelimiting step in the alternative pathway for bile acid synthesis. COCA will then be
synthesized once in the liver.
Figure 3: GABA-ergic chemical library screen of compounds and structures of
COCA, FGIN-1 compounds, and PK11195. A) HuH-7 cells were transfected with 5
µg p(FXRE)4-TK-luc and 0.5 µg pRL-CMV and treated for 24h with GABA-ergic
compounds. Series B-F are single well 10 µM treatments with values reported as fold
change relative to OMSO (control) (n=4). COCA (n=4) is also 10 µM. F2 is FGIN-127, F3 is FGIN-1-43 and FlO is PK11195. B) Chemical structures of compounds
mentioned in A. FGIN-1-27 has six carbons on R3 with fluorine at R1 and hydrogen at
R2. FGIN-1-43 has six carbons on R 3 with chlorine at R1 and R2.
Figure 4: Coactivator recruitment to FXR in mammalian two-hybrid assay. COS1 cells were transfected with 5 µg of pFR-luc, 1.5 µg pM-SRC-1, 1.5 µg VP16-FXR
and 0.5 µg pRL-CMV and treated for 24h. Luciferase activity of each treatment is
reported as fold change relative to OMSO (control) represented by a solid line at 1.
•denotes significance compared to control, p::::; 0.05, (n=8).
Figure 5: Cell line comparison of mRNA expression for proteins involved in FXRmediated bile acid homeostasis. A) Expression of FXR and RXR mRNA in human
hepatocytes, HuH-7, and ZR-75-1 cell lines. Total RNA was reverse transcribed and
cDNA was subjected to actin and select gene-specific amplification with SYBR green
PCR. Gene expression was normalized to actin and expressed as fold relative to
~H1498 mRNA expression (control) (n=2) . B) mRNA expression of nuclear receptors
mvolved in SHP-mediated regulation of bile acids (SHP, LRH-1, and HNF4a) in
HHI 498 and HuH-7. Gene expression was normalized to actin and expressed as fold
relative to HH1498 (control) (n=2). C) HuH-7 cells and D) ZR-75-1 cells were
transfected with 5 µg p(FXRE)4-TK-luc, 0.5 µg pRL-CMV, and 1.25 µg of 3.1-FXR
~MpcDNA3.l(+) empty vector. Luciferase activity for treatments is shown relative to
SO (control) (n=4).
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*

d notes significance compared to control, p :S 0.05; t denotes significance
eared to respective treatment in transfection with no exogenous FXR, p :S 0.05.
comp
f"

re 6: Effects of dose response cotreatments of CDCA with TSPO ligands on
~~-Iuciferase reporter activity. HuH-7 cells were transfected with 5 µg p(FXRE)4TK-luc and 0.5 µg pRL-CMV and treated for 24h with CDCA, FGIN-1-27, FGIN-143 or PKI 1195 at varying concentrations. CDCA and FGIN-1-27 were cotreated with
FGIN-1-43 and PKI 1195 at 10 µM and 1 µM concentrations. CDCA was also
otreated with FGIN-1-27 at 10 µM and 1 µM concentrations. All values (n=4) are
~xpressed as fold relative to DMSO (control) (n=16). CDCA at 10 µMand 100 µM,
n==8. White and dark grey bars represent cotreatments at 10 µM and 1 µM,
respectively, with CDCA or FGIN-1-27 held constant at the noted conce~trat~on. *
denotes significance compared to control, p :S 0.05, represented by solid lme. t
denotes significance compared to respective constant treatment, represented by dotted
line, p :S 0.05.
Figure 7: Expression of BSEP mRNA in response to ligands of FXR and TSPO.
Human hepatocytes (HH1486 and HH1498) and HuH-7 cells were treated for 24h at a
final concentration of 10 µM. Total RNA was reverse transcribed and cDNA was
subjected to actin and BSEP gene-specific amplification with SYBR green PCR.
BSEP expression was normalized to actin and treatments are relative to DMSO
(control) in each experiment. In HH1498 and HuH-7, CDCA and FGIN-1-27 were
cotreated with FGIN-1-43 or PKI 1195. The CDCA and FGIN-1-27 control treatment
values are represented by dotted lines. * denotes significance compared to control, p :S
0.05. t denotes significance compared to respective constant treatment, represented by
dotted line, p :S 0.05, HH1486 (n=3), HH1498 (n=3), and HuH-7 (n=2).
Figure 8: Expression of SHP mRNA in response to ligands of FXR and TSPO.
Human hepatocytes (HH1486 and HH1498) and HuH-7 cells were treated for 24h at a
final concentration of 10 µM. Total RNA was reverse transcribed and cDNA was
subjected to actin and SHP gene-specific amplification with SYBR green PCR. SHP
expression was normalized to actin and treatments are relative to DMSO (control) in
each experiment. In HH1498 and HuH-7, CDCA and FGIN-1-27 were cotreated with
FGIN-1-43 or PKll 195. The CDCA and FGIN-1-27 control treatment values are
represented by dotted lines. * denotes significance compared to control, p :S 0.05. t
denotes significance compared to respective constant treatment, represented by dotted
line, p :S 0.05, HH1486 (n=3), HH1498 (n=3), and HuH-7 (n=2).
Figure 9: Expression of CYP7Al mRNA in human hepatocytes. Human
hepatocytes (HH1486 and HH1498) were treated for 24h at a final concentration of 10
µM. Total RNA was reverse transcribed and cDNA was subjected to actin and
CYP7A1 gene-specific amplification with SYBR green PCR. CYP7A1 expression
was normalized to actin and treatments are relative to DMSO (control) in each
experiment. The schematic illustrates the direct repression of CYP7 Al gene
expression by SHP via indirect FXR ligand activation. * denotes significance
compared to control, p :s 0.05, (n=3).
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F. ure 1O: Crystallized structure of FXR LBD with MF A-1 in the binding pocket
%BID code 3BEJ). Each _a-helix in the LBD is labeled (1-1.2) and v~ries by color
~or simpler visual representation. The small fragment of SRC-1 is shown m green.
figure 11: Molecular modeling of CDCA and TSPO ligands in the LBD of FXR.
Each compound formed various conformations, grouped into clusters, based upon
orientation of each atom deviating by 2.0 A RMS. On the graphs, each bar represents
the number of conformations in a cluster with shared mean free energy of binding ±
SEM. The brackets, labeled a-d, represent the binding energy range for each
conformation based upon core ring orientation. Within each bracket, the hydrocarbon
tails vary in position while the rings maintain the same conformation. The lowest
energy conformers representing the four bracketed conformation types are shown with
key amino acid residues highlighted: T = Thr288, R = Arg331, Y = Tyr369, and H =
His447. Dotted black lines represent hydrogen bonds. Each table shows the frequency
and mean free energy of binding ± SEM for each bracketed conformation. A) CDCA
fit into two conformations from 600 GA runs forming hydrogen bonds with T288 in
conformation a and with R331 and H447 in conformation b. B) FGIN-1-27 formed
four main conformations from 800 GA runs forming hydrogen bonds with T288 in
conformation a and with Y369 in conformation b. C) FGIN-1-20 fit into three
conformations from 800 GA runs forming hydrogen bonds with T288 in conformation
a and H447 in conformation c. D) Four conformations of FGIN-1-51 were formed
from 800 GA runs. E) FGIN-1-43 found four conformations from 800 GA runs. F)
Only one conformation resulted for PKl 1195 from 600 GA runs.
Figure 12: Effects of point mutations of amino acids predicted to interact with
ligands inside the LBD of FXR. A) Two conformations (a and b) of CDCA and four
conformations of FGIN-1-27 (a-d) with the lowest free energy of binding in the LBD
of FXR. Hydrogen bonds to Thr288, Tyr369, His447 and Arg331 are represented by
dotted black line. Residues that directly interact with the ligands are highlighted in
yellow. B) ZR-75-1 cells were transfected with 1 µg of p(FXRE)4 -TK-luc, 100 ng
pRL-CMV, and 500 ng of FXR, either wild type (WT) or hFXR mutant and treated for
24h with a final concentration of 10 µM. * denotes significance compared to control
for each mutation, p :::; 0.05 . (n=4). t denotes significance compared to respective
treatment of WT FXR, p:::; 0.05.
Figure 13: Involvement of FGIN-1-27 in the alternative pathways of bile acid
synthesis and homeostasis. 1) FGIN-1-27 binding to TSPO facilitates the transport of
cholesterol into the mitochondria. 2) The alternative pathway of bile acid synthesis
produces CDCA. 3) CDCA and FGIN-1-27 can both activate FXR to 4) increase
BSEP gene expression.
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8. TABLES

Table 1. GABA-ergic chemical library
~£

C0l1-POUND

GABAer le ACTIVITY

NUMB@

COMPOUND

GABAe~ ACTIVITY

GABA

Endogenous ligand.

07

Chlrnmcthiazolc HCI

NIA

J-Mcthyl-GABA

Activator of GA BA aminotransferase.

08

Primidone

NIA

Gabaculinc

Irreversible inhibitor o GABA
1ransaminasc.

09

Quisqualaminc

GABAa rect..'Plor ligand.

Bl
Bl
Bl

84
Bl

trnns-4-Aminucrolonic add

GABA agonist.

DIO

NCS-382

Antagonist ofGHB.

cis-4-Aminocrotonic acid

GABAc receptor ligand.

Oil

( IS,9R)-b-Hydrastinc

GABAa receptor antagonist.

4.5.6.7_Terrahydroisoxazolo{ 5,4-C lpyridin-

GABAa receptor agonist.

0 12

Picrotoxinin

86

3-ol
GABAc receptor antagonist.

El

5-a-Pregnan-3-a-01-20-one

B7

( 1,2,5,6·Tctmhydropyri din-4.
l)merh I hos hinic acid
CGP 35348

GABAb antagonist.

E2

5-a-Prcgnanc-3-a-2.1-diol-20-one

CGP46381

GABAb antagonist.

E3

Dimethyl Sulfoxidc

CGP 52432

GABAb antagonist.

E4

Pcntylcnetctrazole

NIA

CGP 54626 HCI

GABAb antagonist.

ES

trans-4-Hydroxycrotonic acid

GHB receptor ligand.

CGP55845

GABAb antagonist.

E6

N0-71 1 HCI

GABA nplake inhibitor.

Saclofen HCI

Antagonist at GABAb receptors.

E7

l-Amino-5-bromouracil

Bc01:odiazcpinc I GABA.a ligand

B8
B9
BIO
Bil
812

Cl

GABAa antagonist.

Positive allostcric modula1or of GABAa Cl
channel.
Positive allostcric modulator of GABAa
rccc tors.

Control

SCH 5091 1

GABAb antagonist.

ER

Mcthyl-b-carbolinc-3-carboxylatc

Benzodiazepine inverse agonist.

(midaw k -4-acctic acid HCI

Partial GABAc agonist.

E9

Butyl-b-carbolinc-3-carboxylatc

Endogenous proconnilsant and anxiogenic
benzodiaz.£E.!ne rec~or Ii and.

C4

Riluzole HCI

GABA uptake inhibitor.

E ID

Propyl-b-carboline-3-carboxylate

Bcnzodia.zepine inverse agonist.

Cl

SKF 89976A HCI

GABA uptake inhibitor.

Ell

Ethyl-b-carboline-3-carboxylate

Benzodiazcpinc invL-rsc agonist

C6

Vigabatrin

GABA-T inhibitor.

E12

Chlonnczanonc

NIA

C7

Propofol

GABAa agonist.

Fl

Bcnzodiazcpine receptor inverse agonis1.

F2

FGTN-1-27

Peripheral bcnzodiazepinc receptor ligand

C9

Me1hyl-6,7-dimethoxy-4-ethyl-b-carboline3-carbo~ late
(:1:.)-4-Amino-3-(5-chloro-2-thicnyl)butanoicacid

GABAb agonist.

F3

FGIN-1 -43

Pcriphcral b..::nzodiazcpine receptor ligand

CJO

(:1:.)-Baclofcn

GABAb agonist.

F4

GBLD 345

A high affinily benzodiazepine agonist.

Cit

(-)-Bicuculline mcthobromidc

GABAa antagonist.

F5

N-[-(4-Methoxyphcnyl)cthyl]-3indol.££! o~amide

An inverse agonist al the bcnzodiazcpinc

Cl2

Guvacine HCI

GABA uptake inhibitor.

F6

FG 7142

Inverse agooist and anitiogenic agent.
A non benzodiazcpine BZR agonist.

Cl
C3

C8

7-(Dimcthylcarbamoyloxy)-6-phcnylpyrrolo
Peripheral bcnzodiazepine receptor ligand
_fl, l-Ill.ll .ll_bcnzothia7:£.12.!ne

rec~or.

DI

Jsoguvacine HCI

GABAagonist.

F7

Zopiclone

Dl

Muscimol

GABAa receptor agouisr.

FS

Flumazcnil

Benzodiazepinc :mtagonisr.

Dl

Phaclofcn

GABAb reccptor antagonist.

F9

3-Hydroxymethyl-b-carbolioe

Bcnzodiazcpinc inverse agonisr.

04

SK&F 97541

GABAb agonist.

FI O

PK- 11195

Peripheral bcnzodiazcpinc n:ccptor ligand

Dl

ZAPA H:2S0-1

Agonist at low affinily GABAa receptors.

Fil

lsoniazid

Negative allosterie modulator of GABAa
rCC.£1!.IOrs.

06

Gabazine

Specific GABAa receptor antagonist.

F12

Isonicotinic acid

GABA recc:p1or ligand.
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Table 2. Point mutations ofF'XR amino acids
Seguence !5' - 3'~
283 284 28 5 286
aat ttt etc att
I
N
F
L
aat ttt etc att
I
N
F
L

AA Num.
Codon
AA
Codon Mutation
AA Mutation

326
gaa
E
gaa
E

327
get
A
get
A

32 8
atg
M
atg
M

329
ttc
F
ttc
F

330 [TIT 332 333 334 335 336
ctt cgt tea get gag att ttc
L
R s A E I
F
ctt ctt tea get gag att ttc
L
L
s A E I F

AA Nu m.
Codon
AA
Codon Mutation
AA Mutation

327
get
A
get
A

328
atg
M
atg
M

329
ttc
F
ttc
F

330
ctt
L
ctt
L

331 332 333
cgt tea get
R s A
cgt ttt get
R F A

AA Num.
Codon
AA
Codon Mutation
AA Mutation

364
cct
P
cct
P

365 366 367 368 ~
atg m agt ttt tat
s F y
M F
atg ttt agt ttt ctt
s F L
M F

AA Num.
Codon
AA
Codon Mutation
AA Mutation

442
aca
T
aca
T

443
ttc
F
ttc
F

444
aa t
N
aat
N

445
cat
H
cat
H

287
ttg
L
ttg
L

ms- 289

AA Num.
Codon
AA
Codon Mutation
AA Mutation

446
cac
H
cac
H

290
acg gaa atg
T E M
ctg gaa atg
L
E M

291 292 293
gca ace aat
A
T N
gca ace aat
A
T N

334 335 336 337
gag att ttc aat
I
F N
E
gag att ttc aat
E
I
F N

370 37 1
aaa agt
K s
aaa agt
K s

372
att
I
att
I

373
ggg
G
ggg
G

448 449 450 451
rm
cac get gag atg ctg

Ill

111

374
gaa
E
gaa
E

452
atg
H A
E M
L M
ttc get gag atg ctg atg
F
A
E M
L M
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111

I

Table 3. Forward and reverse oglionucleotide primer sequences for DNA
amplification via SYER Green RT-PCR
5'-3' Sequence
Actin

F - GTTGTCGACGACGAGCG
R-GCACAGAGCCTCGCCTT
BSEP F - CATTTCGCTCTCGATGTTCA
R-TTCCAGGAAAAGCATGTGTG
CYP7Al F- GGTGCAAAGTGAAATCCTCC
R-CAGAACTGAATGACCTGCCA
F - CACAGCGTTTTTGGTAATGC
R-TTGTTTGTGGAGACAGAGCCT
HNF4 F - GGCTGCTGTCCTCATAGCTT
R-GCAGGCTCAAGAAATGCTTC
LRH-1 F- CGGTAAATGTGGTCGAGGAT
R-CGAGTGGGCCAGGAGTAGTA
RXRa F - TGTCAATCAGGCAGTCCTTG
R-GGGTGTACAGCTGCGAGGG
SHP
F - ACTTCACACAGCACCCAGT
R-AGGGACCATCCTCTTCAACC

FXR
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9. FIGURES
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Figure 11 A and B
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Figure 11 C and D

c
FGIN-1-20

/ R _QJ

gJ

~R

_J R

_ci

FGIN-1-20
B1naing En ergy

yATY~T Y ~T
"' 300

c

=
'; 250
e
.s... 200
=
c'.l 150

.... 100

!
j

50

;z:

0

59.55
6.74
33.71

f'cH
l

,.Q

=

c

-8. 7135 ± 0.0078
-8.9750 ± 0.0277
-9.1083 ± 0.0160

o=Q;'.'

b

....0

e

b

frequen cy

a
ri

~

0

a

%

(kca l/mol)

=
=
0

=

=
=

"'

~

......

'

N

l~

H

=

"'
<"f

~

=
=

=

=
=

"'~

<"f

=

"'

~

~

Binding Ener gy (kcal/mol)

D
FGIN-1-51
FGIN-1-51
Bin 1ng En ergy

a
b

c
d

100

"'=
0
90

-:::OI

e...
.sc
....u
...
e
0

.
0

,.Q

---------

.a-,

80
70
60
50
40
30
20

b

c
d

= IO
;z:

0

=
=
0

......

'

Binding E ner gy (kcal/mol)

71

%

(kcal/mol)

frequ e ncy

±
±
±
±

39.97
29.52
15 .09
15 .42

-9.5968
-9.3158
-9.05 19
-8.9140

0.0281
0.0428
0 .0446
0.0498

Figure 11 E and F
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Figure 12
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